Hearing Loss Trial, Completed NCT04200664 Sponsor: University College, London Condition: Hearing Loss
Back to Hearing Loss

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial (NCT04200664) looked at hearing and balance function in people with a condition called idiopathic superficial siderosis (iSS) — a rare condition where iron deposits build up around the brain and spinal cord. The study planned to include three groups: people with iSS, people with age-related hearing loss, and a healthy control group. However, the reported data shows that only the iSS group enrolled any participants — 11 people started the study and 10 completed it. No participants were enrolled in the other two groups, so no comparison data between groups was reported. The reported data shows the results only for the 11 iSS participants. For the pure-tone hearing test — a standard test where a person indicates the quietest sounds they can hear — the average threshold across both ears was reported as 57.3 decibels hearing level (a higher number means quieter sounds are harder to hear). For the tympanogram, a test of how the eardrum moves, all 11 participants returned a normal result. For the auditory brainstem response test, which measures how the hearing nerve and brain respond to sound, 5 participants had an abnormal result, 2 had a normal result, and 4 were inconclusive. For otoacoustic emissions, a test of the tiny hair cells inside the ear, 3 were abnormal, 3 were normal, and 5 were inconclusive. For a speech-in-noise listening test, 4 were abnormal, 1 was normal, and 6 were inconclusive. For balance and vestibular (inner ear) testing, several sub-measures were reported as counts of participants with normal, abnormal, or inconclusive results, though the specific labels for each sub-measure were not included in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Hearing Loss Trial, Completed

NCT04200664
Completed Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Siderosis group: Adults aged 18 or older (male or female) who have been diagnosed with a condition called idiopathic superficial siderosis (iSS) — a specific neurological condition — confirmed by a specialist doctor at University College London Hospitals
  • Age-related hearing loss group: Adults aged 18 or older (male or female) who have been diagnosed with hearing loss caused by aging
  • Control group: Adults aged 18 or older (male or female) who have no history of hearing loss and no known neurological condition affecting their hearing (the trial aims to recruit people aged 50 or above for this group, but may include younger adults if needed)

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • Anyone under the age of 18
  • Anyone whose physical or mental health would prevent them from giving their agreement to take part, or from completing the hearing and/or balance tests involved in the study
  • Siderosis group: Anyone who has not already been formally diagnosed with iSS
  • Age-related hearing loss group: Anyone without a confirmed diagnosis of age-related hearing loss, or whose hearing loss has a different cause; also anyone with a history of exposure to very loud noise, certain medications that can harm hearing, middle ear problems, or a family history of non-age-related hearing loss
  • Control group: Anyone with any known history of hearing loss (for any reason) or any neurological condition affecting hearing; also anyone with a history of exposure to very loud noise, certain medications that can harm hearing, middle ear problems, or a family history of non-age-related hearing loss

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
7 February 2020
Est. completion
19 October 2021

Where this trial was run

🇬🇧 United Kingdom

These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.

Primary endpoints

Hearing Evaluation - Pure Tone Audiometry; Vestibular/Balance Evaluation; Hearing Evaluation - Auditory Brainstem Responses/Acoustic Reflexes; Hearing Evaluation - Tympanogram; Hearing Evaluation - Otoacoustic Emissions; Hearing Evaluation - Listening in Spatialised Sentences Noise Test

Other options

Expanded access pathways

This trial is not enrolling. Other access pathways exist in general: in Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients. Whether it applies to any treatment studied here is a question for your doctor — nothing on this page says it does.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 17 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov